The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, provides insights into the molecular mechanisms underlying the potential efficacy of pivekimab sunirine, a CD123-targeting antibody-drug conjugate (ADC), combined with the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML). Evidence from preclinical studies suggests that venetoclax dampens the DNA damage response induced by this agent for a highly synergistic effect. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Current holder of stock options: Reata Pharmaceuticals
Patents & Royalties: Reata Pharmaceuticals
Consultancy: AbbVie, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Sanofi Aventis, Stemline-Menarini, Vincerx
Research Funding: AbbVie, Ablynx, Allogene, AstraZeneca, Cellectis, Daiichi, FortySeven, Genentech, Gilead, Immunogen, MEI Pharma, Precision Biosciences, Rafael Pharmaceutical, Sanofi Aventis, Stemline-Menarini
